Enzo Biochem Ready to Reveal EGS21 Data (NYSE:ENZ)

Enzo Biochem Inc (NYSE:ENZ) has announced that their Vice President of Corporate Development, David Goldberg will speak about Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 Conference which will be held in Boston on Wednesday, November 18, 2009. The Company announced that Enzo Biochem’s EGS21, an orally administered beta glucosylceramide formulation, which is currently undergoing clinical study, has been named one of this year’s top 10 inflammatory and autoimmune projects to watch. The TA Partnership Conference is sponsored by Windhover Information Inc which is world’s leading publisher of science, technical and health information.

Enzo Biochem have already presented their EGS21 clinical studies data recently at the Liver Conference where they showed that the oral administration of EGS21 is safe and appears to be biologically active in patients with insulin resistance and NASH (non-alcoholic steatohepatitis). Mr. Goldberg stated that this is a welcome recognition by a leading industry information organization and they are pleased to see a positive response. He also mentioned that EGS21 is a formulation derived from Enzo’s pioneering therapeutic platform that utilizes oral immune regulation for immune mediated diseases. Further he said that Enzo Therapeutics subsidiary has always viewed oral immune regulation as an exciting and promising platform and therefore they have continued to pursue through studies involving treatment candidates for unmet medical needs.